The Korean journal of helicobacter and upper gastrointestinal research (대한상부위장관⦁헬리코박터학회지)

Korean College of Helicobacter and upper Gastrointestinal Reseaarch (대한상부위장관ㆍ헬리코박터학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacological Treatment for Peptic Ulcer Bleeding

소화성 궤양 출혈의 약물 치료

  • Ma, Dae Won (Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Byung-Wook (Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 마대원 (가톨릭대학교 의과대학 인천성모병원 내과학교실) ;
  • 김병욱 (가톨릭대학교 의과대학 인천성모병원 내과학교실)
  • Received : 2018.05.28
  • Accepted : 2018.07.04
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Peptic ulcer bleeding (PUB) is the most common cause of non-variceal upper gastrointestinal bleeding, and its frequency has been declining over the past decades. However, mortality from PUB persists, and it is still a serious challenge in clinical practice. Although endoscopic intervention is the basic treatment modality for PUB, pharmacological therapy is an important adjunct. The emergence of proton pump inhibitors (PPIs) enables maintenance of intragastric pH >6, which greatly helps in the treatment of PUB. Continuous intravenous infusion of high-dose PPI reduces the re-bleeding rate, thereby helping avoid additional surgery in patients with high-risk stigmata. Moreover, administration of PPIs prior to endoscopy may reduce the need for additional endoscopic intervention. Recently introduced gastric acid suppressants, such as potassium-competitive acid blockers, have shown promising results in further treatment of PUB.

Keywords

References

  1. Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017;390:613-624. https://doi.org/10.1016/S0140-6736(16)32404-7
  2. Kim JS, Kim BW, Park SM, et al. Factors associated with rebleeding in patients with peptic ulcer bleeding: analysis of the Korean peptic ulcer bleeding (K-PUB) study. Gut Liver 2018;12:271-277. https://doi.org/10.5009/gnl17138
  3. Rosenstock SJ, Moller MH, Larsson H, et al. Improving quality of care in peptic ulcer bleeding: nationwide cohort study of 13,498 consecutive patients in the Danish Clinical Register of Emergency Surgery. Am J Gastroenterol 2013;108:1449-1457. https://doi.org/10.1038/ajg.2013.162
  4. Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Langman M. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994;39:706-712. https://doi.org/10.1007/BF02087411
  5. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336:1054-1058. https://doi.org/10.1056/NEJM199704103361503
  6. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-316. https://doi.org/10.1056/NEJM200008033430501
  7. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978;74:38-43. https://doi.org/10.1016/0016-5085(78)90352-9
  8. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989;30:1704-1707. https://doi.org/10.1136/gut.30.12.1704
  9. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009;150:455-464. https://doi.org/10.7326/0003-4819-150-7-200904070-00105
  10. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006;(1):CD002094.
  11. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677-686. https://doi.org/10.1111/j.1365-2036.2005.02391.x
  12. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-113. https://doi.org/10.7326/0003-4819-152-2-201001190-00009
  13. Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut 2011;60:1170-1177. https://doi.org/10.1136/gut.2010.230292
  14. Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2013;(6):CD007999.
  15. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 2008;134:1836-1841. https://doi.org/10.1053/j.gastro.2008.03.006
  16. Sung JJ, Suen BY, Wu JC, et al. Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Am J Gastroenterol 2014;109:1005-1010. https://doi.org/10.1038/ajg.2014.105
  17. Tsoi KK, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Aliment Pharmacol Ther 2013;38:721-728. https://doi.org/10.1111/apt.12441
  18. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-1762. https://doi.org/10.1001/jamainternmed.2014.4056
  19. Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010;170:751-758. https://doi.org/10.1001/archinternmed.2010.100
  20. Choi KD, Kim N, Jang IJ, et al. Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea. J Gastroenterol Hepatol 2009;24:1617-1624. https://doi.org/10.1111/j.1440-1746.2009.05939.x
  21. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631-1640. https://doi.org/10.1056/NEJMoa065703
  22. Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;(7):CD005415.
  23. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008;6:418-425. https://doi.org/10.1016/j.cgh.2007.12.037
  24. Tsoi KK, Lau JY, Sung JJ. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Gastrointest Endosc 2008;67:1056-1063. https://doi.org/10.1016/j.gie.2007.11.056
  25. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther 2017;45:240-252. https://doi.org/10.1111/apt.13876
  26. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054. https://doi.org/10.1136/bmj.e3054
  27. CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096-1101. https://doi.org/10.1016/S0140-6736(11)60278-X
  28. Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2014;(11):CD006640.
  29. Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a metaanalysis. Ann Intern Med 1997;127:1062-1071. https://doi.org/10.7326/0003-4819-127-12-199712150-00002